| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2902975 | Chest | 2008 | 8 Pages |
Abstract
At 1 year, sitaxsentan therapy appears safe and efficacious for patients with PAH; reductions in mortality and the risk for clinical worsening events provide support for durability of efficacy.
Keywords
PAHendothelin-receptor antagonistSitaxsentanETRAupper limit of normal rangeULNIPAH6MWDALT6-min walk distanceASTAspartate aminotransferaseAlanine aminotransferaseEndothelin antagonistsendothelinBosentanWorld Health Organizationconfidence intervalPulmonary arterial hypertensionIdiopathic pulmonary arterial hypertensionWHOStride
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Raymond L. MD, Robyn J. MD, FCCP, Nazzareno MD, Adaani MD, FCCP, Reda E. MD, Kristin B. MD, FCCP, Charlie MD, FCCP, Carol M. MD, David B. MD, FCCP, Lewis MD, FCCP, Thomas R. PhD, Robert MD,